Jayne Abraham

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial

Howard A. Burris, Takuji Okusaka, Arndt Vogel et al. · The Lancet Oncology · 2024 · 132 citations

Medicine, Oncology, Pharmacology +11

Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma

Bruno Sangro, Peter R. Galle, Robin Kate Kelley et al. · Journal of Clinical Oncology · 2024 · 45 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Patient-reported outcomes for the phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.

Howard A. Burris, Takuji Okusaka, Arndt Vogel et al. · Journal of Clinical Oncology · 2022 · 15 citations

Medicine, Oncology, Pharmacology +11